Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference16 articles.
1. Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 26:dgaa756
2. Solling AS, Tsourdi E, Harslof T, Langdahl BL (2023) Denosumab discontinuation. Curr Osteoporos Rep 21:95–103
3. Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155–e4162
4. Solling AS, Harslof T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36:1245–1254
5. Ferrari S (2022) Short or long-term osteoporosis therapy with denosumab? J Clin Endocrinol Metab 107:e1760–e1762